Harnessing the Power
of Immune Tolerance
Facilitated
Allo-HSCT Therapy
We are developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas.
With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.
Learn more about our therapeutic areas:
Talaris has launched a multi-center, Phase 3 clinical trial of FCR001 in living donor kidney transplant patients, to assess the efficacy and safety of FCR001 in weaning patients off all chronic immunosuppression by twelve months post-transplant.
To learn more about the study and determine if you may be eligible to participate, click here.
Clinical trial details are available here
News
November 22, 2022
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) , a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today... READ MORE
November 10, 2022
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Nov.... READ MORE
